<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874859</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0051</org_study_id>
    <nct_id>NCT02874859</nct_id>
  </id_info>
  <brief_title>Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema</brief_title>
  <acronym>MODEVA</acronym>
  <official_title>Aflibercept Injection for Treatment of Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a non-interventional retrospective study on the efficiency and the tolerance of
      intravitreal injections of Aflibercept on vitrectomized eyes in the diabetic macular oedema
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema (DME) is the leading cause of blindness among people of working age.
      Treatment of DME included blood pressure and glycemic control, grid laser, intravitreal
      injection of steroids (acetonide of triamcinolone, dexamethasone implant, fluocinolone
      implant) or anti-Vascular endothelial growth factor (VEGF) therapy (Bevacizumab, Ranibizumab,
      Aflibercept) (2015). The advent of anti-VEGF therapy has revolutionized the management of
      DME. Aflibercept, one of the drugs in this group has recently been approved in France.
      However, there is no report in the efficacy and tolerance of Aflibercept in vitrectomized
      eyes in the diabetic macular oedema . In this study, in order to prove the efficiency and
      tolerance of Aflibercept, data will be collected in a anonymous way in medical records of
      patients having received a treatment by Aflibercept in the past.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS)</measure>
    <time_frame>12 months</time_frame>
    <description>Estimation of visual acuity after 56 weeks of treatment with Aflibercept</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of the central macular thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Describe the evolution of the Central macular thickness during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of number of Aflibercept injections received</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic vitrectomised patients with macular edema, treated with Aflibercept in the past
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients aged between 19 and 90 years old

          -  Patients with the following characteristics at the beginning of the Aflibercept
             therapy :

        HbA1c &lt; 9% Diabetic macular oedema with the central affected Visual acuity between 1/20 and
        5/40 (between 20 and 70 letters ETRS) Patients who had a vitrectomy over 3 months ago

          -  Patients who did not received an anti-VEGF treatment or any other treatment for their
             diabetic macular edema 3 months before the beginning of the injections

        Exclusion Criteria:

          -  Patients who refused the collection of their data in medical records

          -  Patients with a macular ischemia of more than 1500µm diagnosed via an avascular
             central fluorescein angiography before the inclusion

          -  Patients with a recent cardiovascular incident (heart attack, stroke dating for less
             than 3 months before the inclusion)

          -  Pregnancy at the moment of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thi Ha Chau TRAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupement des Hôpitaux de l'Institut Catholique de Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie lansiaux, MD, PhD</last_name>
    <phone>00 33 3 20 22 52 69</phone>
    <email>lansiaux.amelie@ghicl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marine DESEUR-PYTKOWSKI</last_name>
    <phone>00 33 3 20 22 57 01</phone>
    <email>Pytkowski.marine@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pr MILAZZO Solange</name>
      <address>
        <city>Amiens</city>
        <state>Hauts de France</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange MILAZZO, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tran Thi Ha Chau</name>
      <address>
        <city>Lomme</city>
        <state>Hauts de France</state>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THI HA CHAU TRAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bénédicte DUPAS</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte DUPAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stéphanie BAILLIF</name>
      <address>
        <city>Nice</city>
        <state>Paca</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie BAILLIF, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DIABETIC RETINOPATHY</keyword>
  <keyword>Intravitreal aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

